AI has moved beyond proof-of-concept on the clinical side of pharma, driving rapid discovery of new molecules. But post-market commercialization teams tell a different story: their boards are asking them to use AI to solve the problems caused by multiple rounds of layoffs, mounting pressure to do more with less, and a human capital fabric…
Shots:
AI is redefining compliance from reactive to predictive, as this April edition highlights how AI-powered systems are transforming regulatory oversight into a continuous, real-time, and data-driven function, enabling early risk detection, automated audits, and smarter regulatory collaboration across the pharma value chain.
Strategic dealmaking and AI partnerships shape industry momentum, with March witnessing high-value…
Shots:
AI is redefining visibility in pharma as it becomes the primary gateway to information, requiring companies to shift from content publishing to engineering discoverability with machine-readable, well-cited, and rapidly updated data to be included in AI-generated summaries
Integrated, structured evidence is now critical for success in AI-driven environments, demanding modular, metadata-rich, and consistent data…
Abstract
Just like the Internet in 1990’s, Artificial intelligence is now changing all aspects of our life and work. It’s impact is beginning to show in the industry and it is changing the life-sciences practice by fundamentally altering the way how medicines are discovered, developed, manufactured, approved, supplied and brought to market.
In research and discovery, generative models and structure prediction systems shorten the path from target to lead and raise the ceiling…

